Targeting PD-1/PD-L1 interactions for cancer immunotherapy

被引：293
|
作者：
Zitvogel, Laurence [1 ,2 ,3 ,4 ]
Kroemer, Guido [3 ,5 ,6 ,7 ,8 ]
机构：
[1] Inst Gustave Roussy, INSERM, U1015, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Ctr Clin Invest CBT507, Villejuif, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Univ Paris 11, Villejuif, France
[5] INSERM, U848, Villejuif, France
[6] Ctr Rech Cordeliers, Paris, France
[7] Hop Europeen Georges Pompidou, Paris, France
[8] Univ Paris 05, Fac Med, Paris, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 08期
关键词：
CELL CARCINOMA PATIENTS; CLINICAL-SIGNIFICANCE; PD-1; PATHWAY; B7-H1; EXPRESSION; MOLECULE; IMMUNOSUPPRESSION; RECEPTORS; LIGAND-1; ANTIBODY;
D O I：
10.4161/onci.21335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1223 / 1225
页数：3
相关论文
共 50 条
  • [11] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
  • [12] Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
    Bertucci, Francois
    Goncalves, Anthony
    CURRENT ONCOLOGY REPORTS, 2017, 19 (10)
  • [13] PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
    Hosseinzadeh, Ramin
    Feizisani, Fahimeh
    Shomali, Navid
    Abdelbasset, Walid Kamal
    Hemmatzadeh, Maryam
    Gholizadeh Navashenaq, Jamshid
    Jadidi-Niaragh, Farhad
    Bokov, Dmitry O.
    Janebifam, Morteza
    Mohammadi, Hamed
    IUBMB LIFE, 2021, 73 (11) : 1293 - 1306
  • [14] Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
    Chardin, Laure
    Leary, Alexandra
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [15] Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
    François Bertucci
    Anthony Gonçalves
    Current Oncology Reports, 2017, 19
  • [16] Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
    Li, Chunlin
    Zhang, Nengpan
    Zhou, Jundong
    Ding, Chen
    Jin, Yaqing
    Cui, Xueyuan
    Pu, Kefeng
    Zhu, Yimin
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (02) : 178 - 188
  • [17] The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
    Xu, Yichi
    Song, Gendi
    Xie, Shangdan
    Jiang, Wenxiao
    Chen, Xin
    Chu, Man
    Hu, Xiaoli
    Wang, Zhi-Wei
    MOLECULAR THERAPY, 2021, 29 (06) : 1958 - 1969
  • [18] Targeting PD-1/PD-L1 in lung cancer: current perspectives
    Gonzalez-Cao, Maria
    Karachaliou, Niki
    Viteri, Santiago
    Morales-Espinosa, Daniela
    Teixido, Cristina
    Sanchez Ruiz, Jesus
    Angel Molina-Vila, Miquel
    Santarpia, Mariacarmela
    Rosell, Rafael
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 55 - 70
  • [19] Immunotherapy targeting PD-1/PD-L1: A potential approach for the treatment of cancer bone metastases (Review)
    Hiraga, Toru
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2024, 64 (04)
  • [20] PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
    Huang, Changsheng
    Ren, Shengxiang
    Chen, Yaqi
    Liu, Anyi
    Wu, Qi
    Jiang, Tao
    Lv, Panjing
    Song, Da
    Hu, Fuqing
    Lan, Jingqing
    Sun, Li
    Zheng, Xue
    Luo, Xuelai
    Chu, Qian
    Jia, Keyi
    Li, Yan
    Wang, Jun
    Zou, Caicun
    Hu, Junbo
    Wang, Guihua
    SCIENCE ADVANCES, 2023, 9 (21)
12345